On Monday 08/19/2024 the closing price of the Recursion Pharmaceuticals, Inc Registered Shs -A- share was $7.15 on BTT.
Compared to the opening price on Monday 08/19/2024 on BTT of $6.74, this is a gain of 5.73%.
Recursion Pharmaceuticals, Inc Registered Shs -A-'s market capitalization is $1.91 B by 275.07 M shares outstanding.
Is Recursion Pharmaceuticals, stock a Buy, Sell or Hold?
Recursion Pharmaceuticals, stock has received a consensus rating of buy. The average rating score is and is based on 15 buy ratings, 5 hold ratings, and 0 sell ratings.What was the 52-week low for Recursion Pharmaceuticals, stock?
The low in the last 52 weeks of Recursion Pharmaceuticals, stock was 4.98. According to the current price, Recursion Pharmaceuticals, is 143.72% away from the 52-week low.What was the 52-week high for Recursion Pharmaceuticals, stock?
The high in the last 52 weeks of Recursion Pharmaceuticals, stock was 15.76. According to the current price, Recursion Pharmaceuticals, is 45.37% away from the 52-week high.What are analysts forecasts for Recursion Pharmaceuticals, stock?
The 20 analysts offering price forecasts for Recursion Pharmaceuticals, have a median target of 15.70, with a high estimate of 33.00 and a low estimate of 8.00. The median estimate represents a 45.54 difference from the last price of 7.15.Recursion Pharmaceuticals, A Stock Snapshot
7.15
Bid
200.00
Bid Size
7.16
Ask
700.00
Ask Size
8/19/2024
Date
6:28 PM
Time
241,506.00
Volume
7.16
Prev. Close
6.74
Open
1.90 B
Market Cap in USD
275.07 M
Number of Shares
6.53
Day Low
7.17
Day High
7.15
4.98
52 Week Low
15.76
52 Week High
7.15
0.00
Dividend in USD
0.00
Dividend Yield
78.24
Free Float in %
-1.58
EPS in USD
1.98
Book Value per Share in USD
-1.38
Cash Flow per Share in USD
Recursion Pharmaceuticals, News More News
Historical Prices for Recursion Pharmaceuticals,
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Recursion Pharmaceuticals, Analyst Data
Total Analysts: 20
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 8.00
Median: 15.70
Highest: 33.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Recursion Pharmaceuticals, Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 06/25/24 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 05/10/24 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 04/09/24 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 02/28/24 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 01/16/24 | Needham & Company, LLC | Maintained Buy | $15 | |||
| 11/13/23 | J.P. Morgan | Maintained Hold | $10 | |||
| 11/09/23 | Needham & Company, LLC | Maintained Buy | $15 | |||
| 09/05/23 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 08/09/23 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 07/21/23 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 07/18/23 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 07/13/23 | Morgan Stanley | Maintained Hold | $11 | |||
| 07/12/23 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 07/12/23 | Berenberg | Maintained Buy | $33 | |||
| 05/09/23 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 04/18/23 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 03/16/23 | Needham & Company, LLC | Maintained Buy | $17 | |||
| 01/23/23 | SVB Leerink | Maintained Hold | $8 | |||
| 11/09/22 | Goldman Sachs | Maintained Hold | $9 | |||
| 10/25/22 | SVB Leerink | Maintained Hold | $9 |
Recursion Pharmaceuticals, Estimates* in USD
| 2024 | 2025 | 2026 | |
|---|---|---|---|
| Revenue | 67 | 86 | 121 |
| Dividend | 0.00 | 0.00 | - |
| Dividend Yield (in %) | 0.00 % | 0.00 % | - |
| EPS | -1.56 | -1.75 | -1.35 |
| P/E Ratio | -4.31 | -3.84 | -4.99 |
| EBIT | -395 | -474 | -457 |
| EBITDA | -403 | -519 | -491 |
| Net Profit | -388 | -474 | -450 |
| Net Profit Adjusted | -389 | -403 | -347 |
| Pre-Tax Profit | -369 | -418 | -449 |
| Net Profit (Adjusted) | -392 | -484 | -347 |
| EPS (Non-GAAP) ex. SOE | -1.34 | -1.41 | -1.10 |
| EPS (GAAP) | -1.60 | -1.48 | -1.07 |
| Gross Income | 4 | 6 | 179 |
| Cash Flow from Investing | 338 | 307 | 250 |
| Cash Flow from Operations | -311 | -326 | -270 |
| Cash Flow from Financing | 338 | 307 | 250 |
| Cash Flow per Share | -1.15 | -0.96 | -0.63 |
| Free Cash Flow | -311 | -365 | -221 |
| Free Cash Flow per Share | - | - | - |
| Book Value per Share | 1.67 | 1.06 | 0.77 |
| Net Debt | -316 | -285 | -240 |
| Research & Development Exp. | 279 | 281 | 320 |
| Capital Expenditure | 17 | 17 | 21 |
| Selling, General & Admin. Exp. | 119 | 148 | 165 |
| Shareholder’s Equity | 478 | 473 | 395 |
| Total Assets | 675 | 639 | 625 |
|
Previous Quarter ending 06/30/24 |
Current Quarter ending 09/30/24 |
Next Quarter ending 12/31/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 7 | 7 | 8 | 8 |
| Average Estimate | - | -0.340 USD | -0.446 USD | -1.560 USD | -1.750 USD |
| Year Ago | - | -0.434 USD | -0.399 USD | -1.578 USD | - |
| Publish Date | - | 11/6/2024 | 3/4/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 6 | 7 | 8 | 8 |
| Average Estimate | - | 27 USD | 13 USD | 67 USD | 86 USD |
| Year Ago | - | 11 USD | 11 USD | 45 USD | - |
| Publish Date | - | 11/6/2024 | 3/4/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Sales | 44.58 | 39.84 | 10.18 | 3.96 | 2.32 |
| Change of sales in % | 11.88 | 291.46 | 156.89 | 70.85 | - |
| Gross profit on sales | -6.51 | -8.81 | 1.07 | - | - |
| Gross profit on sales change in % | 26.09 | - | - | - | - |
| Operating income | -350.06 | -245.73 | -182.78 | -84.62 | -62.44 |
| Operating income change in % | -42.46 | -34.44 | -116.01 | -35.51 | - |
| Income before tax | -332.13 | -239.48 | -186.48 | -87.01 | -61.88 |
| Income before tax change in % | -38.69 | -28.42 | -114.33 | -40.61 | - |
| Income after tax | -328.07 | -239.48 | -186.48 | -87.01 | -61.88 |
| Income after tax change in % | -36.99 | -28.42 | -114.33 | -40.61 | - |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total liabilities | 190.26 | 215.48 | 67.41 | 56.56 | 24.59 |
| Long-term liabilities per share | 0.42 | 0.60 | 0.12 | 0.20 | 0.11 |
| Equity | 463.44 | 485.81 | 542.94 | 242.02 | 76.84 |
| Equity change in % | -4.60 | -10.52 | - | -66.01 | - |
| Balance sheet total | 653.70 | 701.29 | 610.35 | 298.59 | 101.43 |
| Balance sheet total change in % | -6.79 | 14.90 | 104.41 | 194.37 | - |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Sales per share | 0.21 | 0.23 | 0.06 | 0.02 | 0.01 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - | - |
| P/E ratio (year end quote, diluted EPS) | - | - | - | - | - |
| P/E ratio (year end quote) | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | - | - |
| Equity ratio in % | 70.89 | 69.27 | 88.96 | -69.09 | -122.51 |
| Debt ratio in % | 29.11 | 30.73 | 11.04 | 18.94 | 24.24 |
Recursion Pharmaceuticals, Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Secora Michael | 08/13/2024 | 15,000.00 | 1,365,343.00 | 6.35 | Sell | No |
| Secora Michael | 08/13/2024 | 39,375.00 | 1,380,343.00 | 2.22 | Buy | No |
| Secora Michael | 08/12/2024 | 15,000.00 | 1,340,968.00 | 6.35 | Sell | No |
| Secora Michael | 08/12/2024 | 39,375.00 | 1,355,968.00 | 2.22 | Buy | No |
| Gibson Christopher | 08/07/2024 | 20,000.00 | 758,738.00 | 6.50 | Sell | No |
| Gibson Christopher | 08/07/2024 | 20,000.00 | 778,738.00 | n/a | Buy | No |
| Gibson Christopher | 08/06/2024 | 30,000.00 | 758,738.00 | 7.10 | Sell | No |
| Gibson Christopher | 08/06/2024 | 30,000.00 | 788,738.00 | n/a | Buy | No |
| Borgeson Blake | 08/05/2024 | 11,447.00 | 7,144,216.00 | 6.82 | Sell | No |
| Khan Najat | 07/31/2024 | 496,972.00 | 496,972.00 | n/a | Buy | No |
| Larson Tina Marriott | 07/24/2024 | 6,000.00 | 535,457.00 | 8.13 | Sell | No |
| Larson Tina Marriott | 07/24/2024 | 6,000.00 | 541,457.00 | 1.06 | Buy | No |
| Borgeson Blake | 07/22/2024 | 11,447.00 | 7,155,663.00 | 8.48 | Sell | No |
| Gibson Christopher | 07/10/2024 | 50,000.00 | 758,738.00 | 7.47 | Sell | No |
| Gibson Christopher | 07/10/2024 | 50,000.00 | 808,738.00 | n/a | Buy | No |
| Gibson Christopher | 07/09/2024 | 25,000.00 | 758,738.00 | n/a | Sell | No |
| Gibson Christopher | 07/09/2024 | 50,000.00 | 758,738.00 | 7.48 | Sell | No |
| Secora Michael | 07/09/2024 | 15,000.00 | 1,316,593.00 | 7.24 | Sell | No |
| Gibson Christopher | 07/09/2024 | 50,000.00 | 808,738.00 | n/a | Buy | No |
| Secora Michael | 07/09/2024 | 39,375.00 | 1,331,593.00 | 2.22 | Buy | No |
| Borgeson Blake | 07/08/2024 | 11,447.00 | 7,167,110.00 | 7.32 | Sell | No |
| Secora Michael | 07/08/2024 | 15,000.00 | 1,292,218.00 | 7.32 | Sell | No |
| Secora Michael | 07/08/2024 | 39,375.00 | 1,307,218.00 | 2.22 | Buy | No |
| Dar Zavain | 06/30/2024 | 1,843.00 | 103,996.00 | n/a | Buy | No |
| Borgeson Blake | 06/30/2024 | 1,441.00 | 7,178,557.00 | n/a | Buy | No |
Recursion Pharmaceuticals, A Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Recursion Pharmaceuticals, Inc Registered Shs -A- | 0.00 | 0.00 | USD |
| 2022 | Recursion Pharmaceuticals, Inc Registered Shs -A- | 0.00 | 0.00 | USD |
| 2021 | Recursion Pharmaceuticals, Inc Registered Shs -A- | 0.00 | 0.00 | USD |
| 2020 | Recursion Pharmaceuticals, Inc Registered Shs -A- | - | - | USD |
| 2019 | Recursion Pharmaceuticals, Inc Registered Shs -A- | - | - | USD |
*Yield of the Respective Date
Recursion Pharmaceuticals, Inc Registered Shs -A- Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | -0.340 USD | Q3 2024 Earnings Release | 11/06/2024 |
| Earnings Report | -0.446 USD | Q4 2024 Earnings Release | 03/04/2025 |
| Earnings Report | -0.513 USD | Q1 2025 Earnings Release | 05/07/2025 |
| Earnings Report | -0.518 USD | Q2 2025 Earnings Release | 08/12/2025 |
Recursion Pharmaceuticals, Inc Registered Shs -A- Past Events
| Event | Actual EPS | Info | Date |
|---|
Recursion Pharmaceuticals, Profile
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Moody’s Daily Credit Risk Score
Recursion Pharmaceuticals, Shareholder
| Owner | in % |
|---|---|
| Freefloat | 78.24 |
| ARK Investment Management LLC | 10.78 |
| Baillie Gifford & Co. | 10.19 |
| Baillie Gifford & Co. | 9.26 |
| ARK Investment Management LLC | 8.84 |
| Vanguard Group, Inc. (Subfiler) | 8.02 |
| Scottish Mortgage Investment Trust Plc | 6.96 |
| ARK Innovation ETF | 6.56 |
| The Vanguard Group, Inc. | 6.00 |
| RA Capital Management LP | 5.89 |
| RA Capital Management LP | 5.89 |
| Mubadala Investment Co. PJSC | 4.97 |
| Mubadala Investment Co. (Investment Company) | 4.97 |
| SSgA Funds Management, Inc. | 4.66 |
| Kinnevik AB | 4.56 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.